FutureMeds strengthens their position in the top tier of Dedicated Research Site Networks in Central and Eastern Europe by expanding into Ukraine.
FutureMeds has acquired site-service organisation Evidence-Based Medicine and Good Clinical Practice Research Institute, LLC (the Institute) with 2 sites in a deal that will give FutureMeds’ clients access to Ukraine, speed-up clinical development and provide patients with new and innovative treatments.
"Ukraine creates a huge potential for our growth and we are delighted to establish a presence in the country. We are determined to bring more clinical studies to Ukraine and offer Ukrainian patients access to future medicine by offering them a chance to participate in clinical trials. We are expecting Ukraine to be one of the fast-growing regions in FutureMeds' global site network and have full confidence in Dr Vyshnyvetskyy and his team's ability to deliver it."
- Dr Radoslaw Janiak, CEO of FutureMeds
FutureMeds’ entry to the Ukraine market followed a pronounced recent increase in clinical trials in the country as well as soaring demand for high-quality, reliable and efficient sites. These trends are projected to stay on a growth path creating an opportunity for FutureMeds to set new standards for running sites, establishing effective site-sponsor collaboration with enhanced data quality and increasing the number of patients that enables trials to be concluded faster.
As an integral part of FutureMeds’ Dedicated Research Site Network, the Institute that was founded in 2017 aims to become the first choice for sponsors in the country going forwards. Strong foundations are already in place: the Institute conducts trials with exclusive agreements in place with City Hospital №1 in Zhytomyr and the Universal Clinic ‘Oberig’ private hospital in Kyiv.
Zhytomyr Dedicated Research Unit in the heart of City Hospital №1 public hospital, where FutureMeds’ Dr. Ivan Vyshnyvetskyy, MD, PhD acts as the Principal Investigator, focuses on General Medicine therapeutic areas such as Rheumatology, Cardiology, Pulmonology, Internal Medicine, COVID-19, Urology and vaccines.
Universal Clinic ‘Oberig’, one of the largest private clinics in Ukraine with cutting-edge diagnostic devices, is particularly suited for Oncology trials.
Acquisition of the sites in Zhytomyr and Oberig represent the next stage of FutureMeds' international expansion. The Institute’s team, projected to grow by 15-20 hires per year to keep up with the demand, adds significant medical expertise to FutureMeds’ current portfolio, broadening the scope of opportunities for research and increasing the number of therapeutic areas.
About FutureMeds
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.